Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade

This study has been completed.
Sponsor:
Information provided by:
Tuscaloosa Research & Education Advancement Corporation
ClinicalTrials.gov Identifier:
NCT00233467
First received: October 3, 2005
Last updated: September 20, 2006
Last verified: September 2006
  Purpose

The main purpose is to show the percentage of patients taking antipsychotics with PTSD by looking at approximately ten year’s worth of data from 1994 through 2004. We will also determine the type and dose of antipsychotics the patients received, and to determine how many of those patients had psychotic versus nonpsychotic symptoms. We will be obtaining this data from the VISN 7 Corporate Data Warehouse. We hypothesize that there has been an overall increase in antipsychotic use in patient’s with PTSD over the last 10 years.


Condition
PTSD
Posttraumatic Stress Disorder

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade

Resource links provided by NLM:


Further study details as provided by Tuscaloosa Research & Education Advancement Corporation:

Estimated Enrollment: 30
Study Start Date: September 2005
Estimated Study Completion Date: September 2005
Detailed Description:

This study is a retrospective chart review of patients, at the Tuscaloosa VA Medical Center, who were, treated with antipsychotics as monotherapy or adjunctive therapy.

The data will be retrieved from a computerized list of patients treated at the TVAMC for PTSD from 1994-2004 Charts will be reviewed by looking at approximately ten year’s worth of data. Charts will then be examined to determine what type of antipsychotics patients were prescribed, the dose and duration of the antipsychotics, and the presence or absence of documented psychotic symptoms.

  Eligibility

Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Have a diagnosis of PTSD (309.81)
  2. Male or female patients at least 19 years of age

Exclusion Criteria:

• None

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00233467

Locations
United States, Alabama
Tuscaloosa VA Medical Center
Tuscaloosa, Alabama, United States, 35404
Sponsors and Collaborators
Tuscaloosa Research & Education Advancement Corporation
Investigators
Principal Investigator: Rebecca Seamans, PharmD Tuscaloosa VA Medical Center
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00233467     History of Changes
Other Study ID Numbers: TREAC Retro PTSD
Study First Received: October 3, 2005
Last Updated: September 20, 2006
Health Authority: United States: Food and Drug Administration

Keywords provided by Tuscaloosa Research & Education Advancement Corporation:
antipsychotics
PTSD
posttraumatic stress disorder

Additional relevant MeSH terms:
Disease
Stress Disorders, Post-Traumatic
Stress Disorders, Traumatic
Anxiety Disorders
Mental Disorders
Pathologic Processes
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents

ClinicalTrials.gov processed this record on November 25, 2014